REG - Irish Takeover Panel - Disclosure Table

The Irish Takeover Panel has disclosed that Mural Oncology plc, Avadel Pharmaceuticals plc, and Permanent TSB Group Holdings plc are in an offer period. Mural Oncology's offeror is XOMA Royalty Corporation, and Avadel Pharmaceuticals' offeror is Alkermes plc. Permanent TSB Group Holdings has no identified offeror. This disclosure is part of the rules of the Irish Takeover Panel, with no specific Rule 2.6(a) deadlines provided for these companies.

RNS Number : 4511K Irish Takeover Panel 05 December 2025

IRISH TAKEOVER PANEL

Disclosure Table

The following companies are deemed to be in an offer period for the purposes of disclosure under the Rules of the Irish Takeover Panel:

_______________________________________________________________

Offeree: Mural Oncology plc

Offer period commenced: 15 April 2025

$0.01 ordinary shares; ISIN: IE000LK2BOB4; NSI: 17,268,881

Offeror: XOMA Royalty Corporation

Disclosure of dealings and positions in this offeror is not required

Offeror identified: 20 August 2025

Rule 2.6(a) deadline: N/A

Offeree: Avadel Pharmaceuticals plc

Offer period commenced: 22 October 2025

$0.01 ordinary shares; ISIN: IE00BDGMC594; NSI: 97,403,364

Offeror: Alkermes plc

Disclosure of dealings and positions in this offeror is not required

Offeror identified: 22 October 2025

Rule 2.6(a) deadline: N/A

Offeree: Permanent TSB Group Holdings plc

Offer period commenced: 30 October 2025

€0.01 ordinary shares; ISIN: IE00BWB8X525; NSI: 544,996,176

Offeror: N/A

Offeror identified: N/A

Rule 2.6(a) deadline: N/A

Irish Takeover Panel 5 December 2025

Lower Ground Floor

76 Merrion Square

Dublin D02 X4T1

Telephone: + 353-1-678 9020

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END ISEGCBDDLBGDGUU